CGA
DXCM icon

Crescent Grove Advisors’s DexCom DXCM Stock Holding History

Crescent Grove Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,388
Closed -$208K – 297
2025
Q2 		$208K Buy
+2,388
New +$187K 0.02% 270
2025
Q1 		– Sell
-2,667
Closed -$207K – 272
2024
Q4 		$207K Buy
+2,667
New +$197K 0.02% 265
2024
Q3 		– Sell
-2,193
Closed -$249K – 283
2024
Q2 		$249K Buy
+2,193
New +$277K 0.03% 239
2023
Q3 		– Sell
-2,002
Closed -$257K – 285
2023
Q2 		$257K Buy
+2,002
New +$242K 0.03% 247
2022
Q2 		– Sell
-1,840
Closed -$235K – 273
2022
Q1 		$235K Hold
1,840
– – 0.02% 262
2021
Q4 		$247K Buy
+1,840
New +$264K 0.02% 258

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Crescent Grove Advisors's DXCM Position: Q3 2025 in Review

Crescent Grove Advisors sold out of DexCom (DXCM) in Q3 2025, closing a stake of 2,388 shares — an estimated $208K sold.

Crescent Grove Advisors first reported a position in DXCM in Q4 2021 and held it in 6 quarters. The position peaked at $257K in Q2 2023. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

  • Crescent Grove Advisors reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
  • Crescent Grove Advisors sold 2,388 DexCom shares in Q3 2025, an estimated $208K.
  • Crescent Grove Advisors first reported a position in DexCom in Q4 2021 and held it in 6 quarters.
  • Crescent Grove Advisors's DexCom position peaked at $257K in Q2 2023.
  • 911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Crescent Grove Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.